Cannabinoid Receptor Inhibitors

CB1

CB2

Cannabinoid Receptor Inhibitors, Agonists, Antagonists, Activators & Modulators

Product Name	CB1	CB2	Purity
Rimonabant Hydrochloride	CB1 , Ki: 1.8 nM		99.95%
Pregnenolone	CB1		99.87%
JD-5037	CB1 , IC₅₀: 1.5 nM		98.05%
SR144528		CB2	99.25%
Anandamide	CB1	CB2	≥99.0%
Rimonabant	CB1 , Ki: 1.8 nM		99.41%
Pregnenolone monosulfate sodium	CB1		≥98.0%
Leelamine	CB1	CB2	98.36%
Yangonin	CB1 , IC₅₀: 1.79 μM CB1 , Ki: 0.72 μM		99.79%
Synaptamide	CB1 , Ki: 633 nM	CB2 , Ki: 3843 nM	≥99.0%
AM281	CB1 , IC₅₀: 9.91 nM	CB2 , IC₅₀: 13000 nM	≥99.0%
CB1 antagonist 4	CB1		99.00%
N-Oleoyl glycine	CB1		≥99.0%
Pregnenolone monosulfate	CB1		99.22%
GW-405833	CB1 , EC₅₀: 16.1 μM	CB2 , EC₅₀: 50.7 nM	99.12%
Leelamine hydrochloride	CB1		99.06%
Bay 59-3074	CB1 , Ki: 48.3 nM	CB2 , Ki: 45.5 nM	99.00%
Etrinabdione		CB2	98.56%
Tedalinab		CB2	99.94%
AZD1940	hCB1-R, pKi: 7.93	hCB2-R, pKi: 9.06	99.45%
CB2R PAM		cannabinoid type-2 receptors	98.46%
GAT211	CB1		99.98%
Tetrahydromagnolol	CB1 , EC₅₀: 9010 nM CB1 , Ki: 2260 nM	CB2 , EC₅₀: 170 nM CB2 , Ki: 416 nM	99.79%
SCH 336		hCB2-R	98.85%
RVD-Hpα TFA	CB1		99.32%
CB1/2 agonist 3	hCB1-R, Ki: 5.9 nM	hCB2-R, Ki: 3.5 nM	99.83%
CB2R antagonist 3		CB2R	98.08%
CB2 modulator 1		CB2	99.02%
PGN36		cannabinoid type-2 receptors, Ki: 0.09 μM	99.74%
2-Palmitoylglycerol	CB1		≥99.0%
Drinabant	rCB1-R, IC₅₀: 10 nM hCB1-R, IC₅₀: 25 nM	CB2 , IC₅₀: 10000 nM	≥99.0%
CB1/2 agonist 1	hCB1-R, EC₅₀: 56.15 nM	cannabinoid type-2 receptors, EC₅₀: 11.63 nM	99.20%
Noladin ether	CB1 , Ki: 21.2 nM	CB2 , Ki: >3 mM	≥98.0%
Auriculasin	CB1 , IC₅₀: 8.92 μM		98.58%
CB2R/FAAH modulator-3	CB1 , Ki: 67.6 nM	CB2 , Ki: 20.1 nM	99.71%
Zevaquenabant	CB1
ANEB-001	CB1
N-Arachidonyldopamine	CB1 , Ki: 250 nM
Eicosapentaenoyl ethanolamide	CB1	CB2
CB1-IN-2	CB1 , IC₅₀: 0.644 μM
CBR Agonist-2	hCB1-R, EC₅₀: 960 nM hCB1-R, Ki: 970 nM
hBChE-IN-2		hCB2-R, IC₅₀: 0.78 μM
URB447	CB1 , IC₅₀: 313 nM
CB2R/FAAH modulator-2	CB1 , Ki: 152.9 nM	CB2 , Ki: 10.8 nM
RTICBM-189	mCB₁, pIC₅₀: 6.25 hCB₁, pIC₅₀: 5.29 CB1 , pIC₅₀: 7.54		99.73%
PM226		CB2 , EC₅₀: 39 nM CB2 , Ki: 13 nM
CB1R Allosteric modulator 1	hCB1-R
MJ15	rCB1-R, IC₅₀: 118.9 pM rCB1-R, Ki: 27.2 pM
NIDA-41020	CB1 , Ki: 4.1 nM
rel-O-2050	CB1
CB1/2 agonist 2	hCB1-R, Ki: 3.5 nM	hCB2-R, Ki: 1.2 nM
LY320135	CB1 , Ki: 141 nM	CB2 , Ki: >10 μM
Pregnenolone (Standard)	CB1
AChE/BChE-IN-18		CB2 , Ki: 31 nM
PSNCBAM-1	hCB1-R, EC₅₀: 0.1 μM		99.48%
RVD-Hpα	CB1
CB1R antagonist 1	hCB1-R, EC₅₀: 10 μM hCB1-R, IC₅₀: 4.2 μM		99.89%
CB1R Allosteric modulator 3	CB1		98.05%
O-2050	CB1 , Ki: 2.5 nM	CB2 , Ki: 0.2 nM
Isopropyl dodec-11-enylfluorophosphonate	CB1 , IC₅₀: 2 μM
(R)-Methanandamide	CB1 , Ki: 20 nM
CB2R agonist 1		CB2R, EC₅₀: 0.56 μM
GW 833972A		hCB2-R, pEC₅₀: 7.3 rat CB2-R, pEC₅₀: 7.5
CB2R/FAAH modulator-1	CB1R, EC₅₀: 489 nM CB1R, Ki: 241.3 nM	CB2R, EC₅₀: 123.6 nM CB2R, Ki: 14.8 nM
Dihomo-γ-Linolenoyl Ethanolamide	hCB1-R, Ki: 857 nM	hCB2-R, Ki: 598 nM
CB2 receptor agonist 2		CB2 , Ki: 8.5 nM
MRL-650	CB1 , IC₅₀: 7.5 nM	CB2 , IC₅₀: 4100 nM
Ibipinabant	CB1 , Ki: 7.8 nM	CB2 , Ki: 7943 nM
CB1R Allosteric modulator 4	hCB1-R
Mead ethanolamide	CB1 , Kd: 753 nM	CB2 , Kd: 1810 nM
CB2 receptor agonist 6		CB2R
CBR Agonist-1	rCB1-R, Ki: 0.18 μM	hCB2-R, Ki: 1.22 μM
BAY 38-7271	CB1 , Ki: 1.85 nM	CB2 , Ki: 5.96 nM
Tocrifluor 1117	CB1
L759633	CB1 , Ki: 1043 nM	CB2 , Ki: 6.4 nM
(R)-(+)-Linoleyl-1'-Hydroxy-2'-Propylamide	CB1 , Ki: 21 μM	CB2 , Ki: 21 μM
(R)-SLV 319	CB1 , Ki: 894 nM
CB1R Allosteric modulator 2	hCB1-R
CB1 inverse agonist 2	CB1 , pKi: 9.7	CB2 , pKi: 6.0
CB2R agonist 3		CB2R, EC₅₀: 0.37 μM
CB2R probe 1		cannabinoid type-2 receptors, Ki: 130 nM
TM38837	CB1
PF-03550096		CB2 , Ki: 7.9 nM
PSB-SB1202	CB1 , EC₅₀: 56 nM CB1 , Ki: 32 nM	CB2 , EC₅₀: 14 nM CB2 , Ki: 49 nM
AM9405	CB1 , IC₅₀: 45.71 nM
Docosatetraenylethanolamide	CB1
CB2R-IN-1		CB2 , Ki: 0.9 nM

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。沪(浦)应急管危经许[2021]201709(QFYS)	站点地图隐私声明
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.	沪ICP备15051369号-4

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。沪(浦)应急管危经许[2021]201709(QFYS)

站点地图隐私声明

Cannabinoid Receptor Inhibitors

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.